John Gittins

Learn More
Current practice for sample size computations in clinical trials is largely based on frequentist or classical methods. These methods have the drawback of requiring a point estimate of the variance of the treatment effect and are based on arbitrary settings of type I and II errors. They also do not directly address the question of achieving the best balance(More)
The behavioural Bayes approach to sample size determination for clinical trials assumes that the number of subsequent patients switching to a new drug from the current drug depends on the strength of the evidence for efficacy and safety that was observed in the clinical trials. The optimal sample size is the one which maximises the expected net benefit of(More)
W ebsite morphing draws on the Expected Gittins' solution to a partially observable Markov process, on the rapid consumer-segment updating with Bayesian methods, and on matching a website's look and feel to a visitor's cognitive style. In each area there are exciting research opportunities including optimality in the presence of switching costs (within a(More)
  • 1